GlassScriptPhysician profile
James M Bresee
NPI 1730484544
$14,299.76
in general payments reported to CMS, 2019-2025
63 companies · $2,700 in 2025
The $2,700 reported for 2025 was more than what 85% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,198 · 2020: $944 · 2021: $600 · 2022: $1,153 · 2023: $2,050 · 2024: $4,654 · 2025: $2,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,487 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,875 · Education: $42.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,486.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,875.00 |
| Education | $42.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,613.44 | 2019-2025 | Rezum Generator, Axonics, Spaceoar Vue System - 10ml |
| Astellas Pharma US INC | $1,319.58 | 2019-2025 | Xtandi, Myrbetriq |
| Sumitomo Pharma America, INC. | $1,022.01 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $935.72 | 2019-2025 | Botox, Lupron Depot |
| Dendreon Pharmaceuticals LLC | $905.52 | 2019-2025 | Provenge |
| Janssen Biotech, INC. | $693.60 | 2019-2025 | Erleada, Talvey |
| Pfizer INC. | $543.29 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $479.41 | 2019-2025 | |
| Accord Healthcare, INC. | $412.53 | 2023-2024 | |
| Tolmar, INC. | $368.86 | 2023-2025 | Eligard, Jatenzo, Rubraca |
| Allergan, INC. | $349.77 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $347.53 | 2019-2025 | Adstiladrin |
| Merck Sharp & Dohme LLC | $270.75 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $270.39 | 2020-2023 | Xgeva |
| Astrazeneca Pharmaceuticals LP | $218.44 | 2022-2025 | Lynparza |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bresee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.